転移性大腸がんの第一線治療における疾患進行リスク - AIOとGONOによる11件の試験の分析
M M Germani1, V Heinemann2, D Rossini3
1Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Roma 67, 56127 Pisa, Italy; Medicine Department of hematology, oncology and tumor immunology, Charitè Universitaetsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
まとめ
転移性大腸がん (mCRC) の病変の進行は6~10ヶ月間でピークに達する. この分析は,患者特有の要因と早期の腫瘍縮小を考慮して,第一線治療における再評価の最適なタイミングを導き出します.
科学分野:
- 腫瘍学
- 臨床試験の分析
- 癌 の 進行
背景:
- 未切除の転移性大腸がん (mCRC) の第一線治療には,化学療法と生物学的薬が含まれています.
- 疾患進行のタイミングを理解することは,治療指針にとって極めて重要です.
研究 の 目的:
- mCRCの第一線治療におけるPDの分布とリスクを評価する.
- 治療中の疾患再評価の最適なタイミングに関するガイドラインを提供すること.
主な方法:
- 11件の臨床試験 (2939例) の個々の患者データを分析した.
- PDイベントの頻度とリスクは,個々の時間点で計算されました.
- 発症前生存率 (PFS) を予測するために,ベースラインの特徴と早期腫瘍収縮 (ETS) を含むコックス回帰モデルを使用した.
主要な成果:
- PDイベントの最大頻度は7. 6ヶ月 (19%の絶対リスク) で発生しました.
- RAS/BRAF野生型 (14ヶ月で23%),RAS変異体 (10ヶ月で25%),BRAF変異体 (8ヶ月で35%).
- ECOG-PS > 0,右側腫瘍,未切開の原発腫瘍,BRAF変異などの要因は独立してPDリスクを増加させたが,ETSはこの影響を軽減した.
結論:
- PDイベント分布は非ガウス型で,第3回と第4回の二ヶ月の再評価の間に最も高い密度があります.
- 切除できないmCRCの場合は,治療開始のみではなく,6〜10ヶ月間の再段階化に焦点を当てます.
- 予測モデルは,患者の特徴,早期の反応,および治療の有効性に基づく放射線学的再評価をスケジュールするのに役立ちます.
関連する概念動画
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:20Comparing the Survival Analysis of Two or More Groups
285
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
285
01:21Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453